Addressing urgent unmet needs in rare diseases
At Hansa Biopharma, we are on a mission to develop innovative immunomodulatory treatments and bring them to those patients whose medical needs have been overlooked.
This is Hansa“We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological conditions.”
Søren Tulstrup, President and CEO
17
Years of innovation
11
Clinical and preclinical programs
+30
Nationalities represented in our workforce
Media
Our latest press releases
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
05/09/2024
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
23/08/2024
Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
Regulatory press release
18/07/2024
Hansa Biopharma to host Q2 2024 interim results conference call
03/07/2024
Our Technology platform
Our unique antibody-cleaving enzyme technology
We have developed our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.
Media
News and insights
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Addressing barriers to gene therapy treatment
31/01/2024
Therapeutic Areas
Our unique enzyme technology has the potential to transform the lives of people affected by rare immunologic conditions, including transplant rejection, genetic diseases, autoimmune conditions, and cancer.
Melissa. Highly sensitized kidney patient on dialysis, USA.
Sustainability
We are the bigger picture
Since 2007, we have been fully committed to those living with rare conditions and have worked to develop lifesaving and life altering therapies through pioneering research and innovation. We strive to live up to the high ethical standards we set for ourselves, and to be a force for good both for individuals and society as a whole.
Our commitmentA truly great place to work
Our strong company culture is what led us to be awarded Great Place to Work for four consecutive years from 2020 to 2023, by the independent institute Great Place to Work®, a global authority on workplace culture, employee experience and leadership behavior. In addition, Hansa has been selected among the best workplaces in Sweden in 2023.
Patient stories
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patient stories
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
Patient stories
Taking care of a transplanted kidney through physical and mental health
“And people say to me: I never would have guessed that you had a kidney transplant… when I hear those words, they keep me motivated, and keep me going.”
Employee stories
Working in an epicentre of pioneering innovation
“The key to our collective success at Hansa Biopharma goes far beyond our scientific breakthroughs, as it stems from the amazing team spirit we have built.”
Ready for a new career? Join us
